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Background: Direct comparisons between countries in 
core HIV care parameters are often hampered by dif-
ferences in data collection. Aim: Within the EuroSIDA 
study, we compared levels of antiretroviral treat-
ment (ART) coverage and virological suppression (HIV 
RNA < 500 copies/mL) across Europe and explored 
temporal trends. Methods: In three cross-sectional 
analyses in 2004–05, 2009–10 and 2014–15, we 
assessed country-specific percentages of ART cover-
age and virological suppression among those on ART. 
Temporal changes were analysed using logistic regres-
sion. Results: Overall, the percentage of people on ART 
increased from 2004–05 (67.8%) to 2014–15 (78.2%), 
as did the percentage among those on ART who were 
virologically suppressed (75.2% in 2004–05, 87.7% 
in 2014–15). However, the rate of improvement over 
time varied significantly between regions (p < 0.01). 
In 2014–15, six of 34 countries had both ART cover-
age and virological suppression of above 90% among 
those on ART. The pattern varied substantially across 
clinics within countries, with ART coverage ranging 
from 61.9% to 97.0% and virological suppression from 
32.2% to 100%. Compared with Western Europe (as 
defined in this study), patients in other regions were 
less likely to be virologically suppressed in 2014–15, 
with the lowest odds of suppression (adjusted odds 
ratio = 0.16; 95% confidence interval (CI): 0.13–0.21) in 
Eastern Europe. Conclusions: Despite overall improve-
ments over a decade, we found persistent disparities 
in country-specific estimates of ART coverage and 
virological suppression. Underlying reasons for this 
variation warrant further analysis to identify a best 
practice and benchmark HIV care across EuroSIDA.
Background 
It is documented that large health inequalities exist 
across Europe among people living with HIV (PLHIV) as 
well as for other diseases [1-4]. In recent years, com-
paring and characterising differences in healthcare 
between countries has received growing interest and 
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has become a central component of informing and tar-
geting health policies. Since it was first introduced, 
the HIV care continuum has been widely adopted as a 
tool to benchmark the quality of HIV care [2,5,6], and 
there are several examples of national and local HIV 
care continua, including a number of European coun-
tries [7-17]. The 90–90–90 targets, launched by the 
Joint United Nations Programme on HIV/AIDS (UNAIDS) 
in 2014, aim to set goals for improving the HIV contin-
uum of care from diagnosis to virological suppression 
[18]. More specifically, they state that at least 90% of 
PLHIV should be aware of their status, at least 90% of 
people diagnosed with HIV should receive antiretrovi-
ral therapy (ART) and at least 90% of those should be 
virologically suppressed. If these targets are reached 
by 2020, ending the AIDS epidemic by 2030 should 
be within reach [18]. It is clear that some countries are 
close to reaching the targets while others still have 
a long way to go [2,19,20]. However, in the absence 
of common definitions for the different steps of the 
Figure 1
Country-specific estimates of the percentage of people on ART among those in care, and percentage of people virologically 
suppressed among those on ART, EuroSIDA study, 2004–05, 2009–10 and 2014–15
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care continuum, country-to-country comparisons have 
proven difficult [2,6,20-22]. Furthermore, differences 
in the data sources used to construct the continua of 
care further complicate international comparisons.
Previous studies comparing the HIV care continuum 
across countries have been limited by such differences 
in data collection [19,20], and there is currently a lack 
of studies with access to internationally comparable 
data. EuroSIDA has a unique set-up which allows direct 
comparisons of data between countries. The aims of 
this study were to characterise country-specific levels 
of antiretroviral coverage and ART-induced HIV RNA 
suppression within the EuroSIDA study, and to monitor 
temporal trends.
Methods
Patients
The EuroSIDA cohort study includes data from (as at 
May 2017) 23,043 PLHIV 16 years or older and enrolled 
in HIV care at 100 HIV outpatient facilities in 33 coun-
tries across continental Europe as well as Israel and 
Argentina. Details about the study have been published 
elsewhere [23]. In brief, EuroSIDA collects patient 
information that is routinely recorded at the collabo-
rating sites. Data are reported to EuroSIDA on stand-
ardised data collection forms, first at enrolment into 
the study, and thereafter at 6-month intervals. At each 
data collection, demographic and clinical data, includ-
ing all CD4+ T-cell counts and HIV RNA measurements, 
data about ongoing ART and reasons for stopping or 
switching treatment, date of diagnosis of any AIDS- or 
non-AIDS-defining illness, and information about cause 
of death is recorded. Data quality assurance includes 
site visits with source verification of all major clinical 
events and monitoring data from a random selection 
of patients followed at each site. EuroSIDA is an open 
cohort, and in the period from 2004 to 2016, addi-
tional patients and sites were recruited in four recruit-
ment waves in 2005 (n = 2,500), 2008 (n = 2,500), 2012 
(n = 2,500) and 2014–2016 (n = 4,000). Details about 
loss to follow-up within EuroSIDA have previously been 
reported [24].
Definitions
EuroSIDA participants were followed from recruitment 
into EuroSIDA until the latest CD4+ T-cell measurement, 
HIV RNA-measurement, date of most recent visit to 
clinic, or death. In three a priori defined time periods, 
Figure 2
Temporal trends in unadjusted estimates of the percentage on ART among those in care and percentage virologically 
suppressed among those on ART by region and overall, EuroSIDA study, 2004–05, 2009–10 and 2014–15
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a person was considered ‘in care’ if their first EuroSIDA 
visit occurred before the end of the time period 
assessed and their latest recorded visit or CD4+  T-cell 
count or HIV RNA measurement occurred after the 
beginning of the time period assessed. People were 
assessed for being ‘in care’, ‘on ART’ or ‘virologically 
suppressed’ at the latest of a clinic visit, a CD4+ T-cell 
or an HIV RNA-measurement in each time period. 
If neither was available, the midpoint of the period 
was used. A 12 months window was allowed before 
the assessment date. This means that if a clinic visit 
date or a CD4+  T-cell count (and date) was available 
within the period assessed, an HIV RNA measurement 
within 12 months prior to that date could be included 
in analyses. The outcomes of interest were country-
specific percentages of ‘on ART’, defined as the number 
of people receiving ART among those in care, and of 
‘virologically suppressed’, defined as the number of 
people with HIV RNA (most recent measurement) below 
500 copies/mL among those on ART. ART was defined 
as receiving at least three antiretroviral drugs from any 
class. The cut-off of 500 copies/mL was chosen as not 
all countries have access to assays with a lower limit 
of detection of 50 copies/mL. A person in care but with 
no available HIV RNA measurement within the time 
period assessed, was considered virologically unsup-
pressed (missing = failure). People who were followed 
in EuroSIDA during more than one of the time periods 
assessed could contribute data to more than one time 
period. In sensitivity analyses, we assessed the influ-
ence of recent recruitment into EuroSIDA and of using 
an HIV RNA detection limit of 50 copies/mL.
Statistical analyses
In repeated cross-sectional analyses, we compared 
country- and region-specific percentages of people on 
ART and virologically suppressed in three time peri-
ods: 1 January 2004 to 31 December 2005, 1 January 
2009 to 31 December 2010, and 1 January 2014 to 31 
December 2015. Country-level estimates were based 
on pooled results from active EuroSIDA clinics in the 
country during each time period, and were grouped into 
regions as listed in  Table 1. Because this study had a 
European focus, data from Argentinian clinics were not 
Figure 3
Adjusted odds ratio of being on ART among those in care and of being virologically suppressed among those on ART in 
2009–10 and 2014–15 compared with 2004–05 by region, EuroSIDA study
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included in analyses. Israel is part of the World Health 
Organisation European Region and was included in the 
Southern European region, as per EuroSIDA tradition. 
We chose not to report individual country estimates 
based on fewer than 30 people.
Trends over calendar time were analysed using logis-
tic regression with generalised estimating equations, 
accounting for repeated measurements and adjusting 
for basic patient characteristics that were thought to 
vary significantly between regions over time, includ-
ing current age, sex, mode of infection, CD4+  T-cells 
at entry into EuroSIDA, and current hepatitis B and 
hepatitis C status. Formal tests for interaction between 
regions and time were performed.
Figure 4
Adjusted odds ratio of being on ART among those in care, of being virologically suppressed among those on ART, and 
of being virologically suppressed among those with an available HIV RNA measurement, EuroSIDA study, 2014–2015 
(n = 12,825)
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Results
Patient and clinic characteristics
Table 2  shows the characteristics of patients and 
clinics included in analyses during the three time 
periods. 12,825 people were under follow-up in the 
2014–15-cohort in 105 clinics in 34 countries. Of them 
10,034 (78.2%) patients were on ART and of those, 
8,803 (87.7%) patients were virologically suppressed. 
A total of 758 people on ART (7.5%) did not have HIV 
RNA measurements in the 2014–15 study period. The 
percentage of people without available HIV RNA meas-
urement were equally distributed across Southern 
Europe (6.7%), Northern Europe (9.5%), East Central 
Europe (9.5%), and Eastern Europe (11.6%), but was 
lower in Western Europe (2.1%). The percentage with-
out available HIV RNA measurement in 2014–15 varied 
between 58.3% of those on ART in one country, to less 
than 1% in three countries.
The median age of the study population increased over 
the three time periods and was 48.3 years (interquar-
tile range: 39.9–54.7) in 2014–15. Patients were pre-
dominantly male (72.9% in 2014–15) and throughout 
the study period, the predominant mode of infection 
was sex between men (37.2% in 2014–15), followed by 
heterosexual transmission (29.2%) and injection drug 
use (26.2%). As EuroSIDA included new clinics and 
patients over time, the number of people enrolled in 
East Central and Eastern Europe increased, changing 
the relative distribution between regions over time. Of 
the total 16,826 people included across all three time 
periods, 9,224 (54.8%) contributed data to more than 
one time period.
Overall, 280 patients (10.0%) of 2,791 who did not 
receive ART in 2014–15 had a CD4+  T-cell count below 
200 cells/mL. This percentage was higher in in Eastern 
Europe (20.0%) than in the other regions (Western 
Europe 9.8%, Southern Europe 5.5%, Northern Europe 
3.6%, East Central Europe 11.8%, p for difference 
across regions < 0.0001)
Country-specific levels of ART coverage and 
virologically suppressed among those on ART
Figure 1  shows unadjusted country-level estimates of 
the percentage of people on ART among those in care 
and the percentage virologically suppressed among 
those on ART in the three time periods. Each country 
is represented by a bubble and the area of each bub-
ble is proportional to the total number of people under 
follow-up in each country during each time period. 
Individual country estimates based on fewer than 30 
people are not shown. In 2014–15 (Figure 1C) the high-
est-ranking country had an ART coverage of 97.0%, and 
all of those were virologically suppressed. The coun-
try with the lowest percentage on ART was a country 
in Southern Europe with 61.9% on ART among those 
in care, and the country with the lowest percentage 
virologically suppressed was a country in East Central 
Europe, where 32.2% of those on ART were virologi-
cally suppressed. Fourteen of 34 countries had levels 
of virological suppression among those on ART below 
90%. In six of 34 countries, more than 90% were on 
ART and more than 90% were virologically suppressed 
among those on ART, while 11 of 34 countries reached 
neither target in 2014–15.
Temporal trends
Figure 2A shows how crude estimates of the percentage 
of people on ART changed over time, overall and by 
region. Overall, the percentage of people receiving 
ART increased from 67.8% in 2004–05 to 78.2% in 
2014–15. The level of ART coverage varied substantially 
between regions, but changed over time to become 
more consistent across regions (p < 0.01 for interaction, 
Figure 3A). For example, ART coverage was low in 
Eastern Europe in 2004–05, but people in this region 
were 13 times more likely to receive ART in 2014–15 
compared with 2004–05 (adjusted odds ratio (aOR) 
on ART = 13.00; 95% confidence interval (CI): 10.46–
16.15). In Western Europe, ART coverage in 2004–05 
was higher and the odds of receiving ART increased cor-
respondingly less over time (on ART 2014–15 vs 2004–
05: aOR = 1.14; 95% CI: 1.00–1.29). While ART coverage 
Table 1
Definition of European regions for his study, EuroSIDA study, 2004–2015 (n = 35 countries)
Western Europe Southern Europe Northern Europe East Central Europe Eastern Europe
Austria Greece Denmark Bosnia-Herzegovinaa Belarus
Belgium Israel Finland Croatiaa Estonia
France Italy Icelanda Czech Republic Georgiaa
Germany Portugal Ireland Hungary Latvia
Luxembourg Spain The Netherlands Poland Lithuania
Switzerland Norway Romania Russia
Sweden Serbia Ukraine
United Kingdom
Slovakiab
Sloveniaa
a Countries included only in the 2014–15 cohort.
b Countries included only in the 2004–05 cohort.
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increased between 2004–05 and 2009–10, levels 
seemed to reach a plateau in recent years in Northern 
Europe (on ART 2014–15 vs 2004–05: aOR = 2.01; 95% 
CI: 1.73–2.34) and declined slightly in Southern Europe 
(aOR = 0.77; 95% CI: 0.68–0.87).
The crude percentage of people who were virologi-
cally suppressed among those on ART also increased 
over time (Figure 2B), and the change over time again 
varied between regions (p < 0.01 for interaction, Figure 
3B). This ranged from a 46% increase in East Central 
Europe (virologically suppressed 2014–15 vs 2004–05: 
aOR = 1.46; 95% CI: 1.17–1.82) and a 47% increase 
in Northern Europe (aOR = 1.47; 95% CI: 1.22–1.77), 
to a more than threefold increase in Southern 
Europe (aOR = 3.46; 95% CI: 2.91–4.11). The largest 
Table 2
Characteristics of patients and clinics included in analyses during the three time periods, EuroSIDA study, 2004–05, 
2009–10 and 2014–15
2004–05 2009–10 2014–15
Number of clinics included 96 100 105
Total number of patients included 8,743 10,013 12,825
Median number of patients per clinic, n (IQR) 74 (39–114) 90 (49–136) 108 (64–167)
Age in years, median (IQR) 40.9 (35.6–47.8) 44.9 (37.8–51.8) 48.3 (39.9–54.7)
n % n % n %
Sex
Male 6,543 74.8 7,257 72.5 9,352 72.9
Female 2,200 25.2 2,756 27.5 3,473 27.1
Region of residence
Western Europe 2,137 24.4 2,385 23.8 3,033 23.6
Southern Europe 2,586 29.6 2,420 24.2 2,957 23.1
Northern Europe 2,218 25.4 2,319 23.2 2,902 22.6
East Central Europe 975 11.2 1,409 14.1 1,934 15.1
Eastern Europe 827 9.5 1,480 14.8 1,999 15.6
Mode of infection
MSM 3,692 42.2 4,143 41.4 4,772 37.2
PWID 2,053 23.5 2,087 20.8 3,363 26.2
Heterosexual 2,432 27.8 3,084 30.8 3,750 29.2
Other/unknown 566 6.5 699 7.0 940 7.3
Number of patients on ART, % of total 5,928 67.8 7,687 76.8 10,034 78.2
By mode of infection, % of risk group
MSM 2,774 75.1 3,364 81.2 3,845 80.6
PWID 1,171 57.0 1,421 68.1 2,439 72.5
Heterosexual 1,560 64.1 2,347 76.1 2,997 79.9
Other/unknown 423 74.7 555 79.4 753 80.1
Patients not receiving ART with CD4+ T-cell count < 200 cells/mL, % of those not 
on ART 405 14.4 192 8.3 280 10.0
By region of residence, % of those not on ART in that region
Western Europe 81 13.0 36 6.7 75 9.8
Southern Europe 92 14.4 32 7.0 44 5.5
Northern Europe 98 19.4 18 6.4 13 3.6
East Central Europe 66 19.4 20 6.7 34 11.8
Eastern Europe 68 9.6 86 11.4 114 20.0
Patients with missing information on HIV RNA among those on ART, % of total 
on ART 188 3.2 455 5.9 758 7.6
Patients with HIV RNA < 500 copies/mL among those on ART, % of total on ART 4,460 75.2 6,777 88.2 8,803 87.7
By mode of infection, % of risk group on ART
MSM 2,136 77.0 3,107 92.4 3,523 91.6
PWID 861 73.5 1,135 79.9 1,976 81.0
Heterosexual 1,152 73.8 2,036 86.7 2,631 87.8
Other/unknown 311 73.5 499 89.9 673 89.4
ART: antiretroviral treatment; IQR: interquartile range; MSM: men who have sex with men; PWID: people who inject drugs.
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improvements over time were observed in Western 
Europe, where the odds of virological suppression 
were more than six times higher (aOR = 6.40; 95% CI: 
5.03–8.14) in 2014–15 compared with 2004–05, and 
in Eastern Europe with a fourfold increase in the odds 
of virological suppression (aOR = 3.97; 95% CI: 2.71–
5.82) over the decade.
Regional variability
Figure 4A  shows the 2014–15 estimates of the 
unadjusted and adjusted odds of receiving ART across 
the five regions. Compared with Western Europe, 
people in Northern Europe (aOR on ART = 2.35; 95% CI: 
2.04–2.70) and East Central Europe (aOR = 2.39; 95% 
CI: 2.05–2.78) were more likely to receive ART in both 
unadjusted and adjusted models. Conversely, in unad-
justed estimates, people in Eastern Europe (OR = 0.83; 
95% CI: 0.74–0.94) were less likely to receive ART, but 
after adjustment, the odds of being on ART were higher 
in Eastern compared with Western Europe (aOR = 1.23; 
95% CI: 1.07–1.41). There was no evidence of differ-
ences in ART coverage between Western and Southern 
Europe (aOR = 1.07; 95% CI: 0.96–1.20).
 
Figure 4B  shows the 2014–15 estimates of the 
unadjusted and adjusted odds of virological suppres-
sion among those on ART, comparing across regions. 
Compared with Western Europe, patients in all other 
regions were less likely to be virologically suppressed 
in 2014–15.
Sensitivity analyses
In sensitivity analyses, differences in the availability 
of HIV RNA measurements seemed to explain some 
of the differences between regions (Figure 4C). Thus, 
the lower odds of virological suppression observed 
in Northern Europe disappeared when excluding peo-
ple with missing HIV RNA measurements in 2014–15 
(aOR = 0.96; 95% CI: 0.63–1.47) and were attenuated 
in East Central and Southern Europe. Conversely, the 
lower odds of virological suppression remained for 
people in Eastern Europe, even when excluding those 
with missing HIV RNA measurements (aOR = 0.13; 95% 
CI: 0.09–0.18).
EuroSIDA is an open cohort, and the latest enrolment 
wave was 2014–16. To account for differences in ART 
coverage and virological suppression among these 
newly enrolled patients, we performed sensitivity anal-
yses excluding 2,893 patients recruited into EuroSIDA 
in 2014–15. Excluding these patients yielded overall 
comparable results, although unadjusted point esti-
mates for some individual countries did change (data 
not shown).
Discussion
In this study we provide a picture of variation in ART 
coverage and virological suppression in a large num-
ber of clinics across 34 countries in Europe including 
Israel, and describe trends over the last decade. We 
found that overall, ART coverage increased between 
2004–05 and 2014–15, as did the percentage of people 
with suppressed viral load among those on ART, but 
these overall improvements covered very large differ-
ences in country-specific estimates and trends in ART 
uptake and virological suppression. We also found that 
in 2014–15, 14 of 34 countries did not reach the goal of 
virological suppression in at least 90% of those on ART 
among those persons included in EuroSIDA.
Our data help illustrate that countries may have very dif-
ferent challenges in improving outcomes along the con-
tinuum of care. Following the findings of the Strategic 
Timing of Antiretroviral Therapy (START) study [25] and 
the subsequent adaptation of clinical guidelines to ini-
tiate ART in any person regardless of CD4+ T-cell count 
[26,27], we may expect ART coverage to increase in the 
years to come, although not all countries have adapted 
the recommendations in national clinical guidelines. 
Expanding the use of ART will require substantial fund-
ing, especially in countries where ART coverage is low. 
Further, although countries in Eastern Europe experi-
enced the largest improvements in ART coverage over 
time, some of these countries also have the highest 
burden of HIV and are likely to face a range of chal-
lenges with scaling up their ART programmes.
We chose to include patients with missing HIV RNA 
measurements in our analyses, while others have 
attempted to statistically account for [9,28,29] or 
exclude [7] those with missing values. Our approach 
may underestimate the true number of people with 
suppressed HIV RNA, whereas excluding all with miss-
ing HIV RNA measurements is likely to overestimate the 
percentage of people successfully managed. HIV RNA 
measurements may be missing for people who receive 
ART for many reasons, including irregular clinic attend-
ance, patient refusal, poor access or limited resources 
for laboratory monitoring. Measurements may also 
be missing at clinics with reporting delays or at sites 
that have reported incomplete data. We were not able 
to distinguish between these different causes which 
may have very different implications for the individual 
patient. However, it is worth noting that the observed 
differences in levels of virological suppression were 
not explained by differences in the availability of HIV 
RNA measurements. Also, our window for including an 
HIV RNA measurement was broad, and we find it rea-
sonable to assume that a patient without available HIV 
RNA measurement within a 2-year period is not suc-
cessfully managed and may signal a potential oppor-
tunity for intervention or a missed opportunity for 
retaining a patient in care, in particular in the 2014–15 
study period. Furthermore, a lack of data may in itself 
be a sign of possible gaps in performance and may 
thus equally be a sign of an opportunity for interven-
tion [30].
Our definition of virological suppression was based 
on a single HIV RNA measurement below 500 copies/
mL. In a previous study we showed that current viral 
load was as good as repeated HIV RNA measurements 
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to evaluate quality of ART care [31]. This is also in line 
with strategies recommended by the European Centre 
for Disease Prevention and Control (ECDC) and UNAIDS 
[2,18]. However, some may consider this a liberal defi-
nition of virological suppression and may argue that 
confirmed measurements are more reliable. If this 
is true, we expect that our findings overestimate the 
percentages of people with virological suppression. 
Our analyses do not account for virological ‘blips’, 
commonly observed in the clinic [32], and we may be 
underestimating the true number achieving virological 
suppression. We have no evidence that the frequency 
of ‘blips’ would vary between countries. On the other 
hand, our cut-off for virological suppression was high 
(500 copies/mL), which should reduce the effect of this 
bias.
Some major strengths of this study should be men-
tioned. Firstly, we had access to data from a large 
number of countries, including some with no national 
data collection structure. Secondly, and in contrast to 
previous studies [2,19,20], we were able to compare 
data directly across countries as data was collected in 
a uniform manner in all countries and across all three 
time periods. Previous studies have not been able to 
describe temporal trends, largely due to insufficient 
follow-up and changes in definitions over time [33]. 
Finally, we had access to complete data on ART cover-
age among those followed in EuroSIDA, which is not 
often readily available in registry studies.
A limitation of our study is that data were based 
solely on clinics contributing to the EuroSIDA study, 
which may not be representative of nation-wide care. 
EuroSIDA is an open cohort and therefore, differences 
over time may also reflect recruitment patterns over 
time. Although not a recommended standard treat-
ment strategy in current guidelines [26,27], switching 
ART in stable patients with undetectable viral load 
to dual therapy regimens has gained some ground in 
recent years [26,34,35]. Our definition of ART does not 
capture patients on such regimens, which may lead to 
an underestimation of ART coverage. Also, we did not 
take eligibility for ART into consideration when describ-
ing trends in ART uptake over time. In this context it is 
important to underline that this study did not aim to 
evaluate adherence to guidelines. Furthermore, it is 
worth keeping in mind that, while guidelines for when 
to start ART have changed over time, the goal of viro-
logical suppression among those on ART has not.
Partly due to our study design, we used the definition 
‘on ART among those in care’ rather than among those 
diagnosed. Compared with the UNAIDS 90–90–90 
definition of ‘on ART’ [18], we expect that our esti-
mates of ART coverage are higher, as the denominator 
includes only those in care, and the true between-
country variation in ART coverage may thus be even 
more pronounced than what we observed. On the other 
hand, our definition allowed us to directly compare 
performance at the clinic level without considering the 
impact of variation in linkage to care.
Between-country variation in HIV treatment and care 
is likely to reflect a complexity of underlying reasons 
including differences in patient populations, patient 
management, healthcare structures, policies, health 
expenditure, varying local treatment guidelines and 
more. In addition to presenting the unadjusted, coun-
try-specific estimates that are usually presented in 
cascades of care, we evaluated the odds of receiv-
ing ART and being virologically suppressed on ART 
across regions. In these analyses, we chose to adjust 
for basic patient characteristics that were expected 
to vary across regions and over time. One advantage 
of the unadjusted snapshot approach is that the esti-
mates are easy to interpret and to communicate, e.g. 
to policymakers. However, we believe that the adjusted 
analyses add to the understanding of how much of the 
regional variation may be attributed to differences in 
patient characteristics and how much may be attrib-
utable to differences in the quality of care, which 
could be targeted in health policy interventions. For 
example, in unadjusted estimates, people in Eastern 
Europe were less likely than people in Western Europe 
to receive ART. However, after adjustment, the odds of 
receiving ART were higher in Eastern Europe, indicat-
ing that some of the differences in ART coverage in the 
two regions may be explained by differences in patient 
characteristics. Needless to say, our analyses are only 
one step towards understanding the complex interplay 
of factors that lead to variation. However, we believe 
that our study may help identify potential gaps in care 
and may help frame new questions that will give us a 
better understanding of the causes of variation in the 
quality of HIV care. One gap in care within the individ-
ual regions has been identified for people who inject 
drugs [36]. In this context, our findings emphasise the 
need to continue monitoring the response to the HIV 
epidemic and to construct high-quality data collection 
that may serve as a platform for both local monitoring 
and international comparisons.
Conclusion
We were able to directly compare data from a large 
number of clinics across Europe, including some coun-
tries that do not have national registries. We found 
persistent between-country disparities in the level of 
ART coverage and virological suppression, as well as 
the rate of improvement over the last decade. EuroSIDA 
will continue the surveillance of changes and variation 
in countries’ performance in the ‘test and treat’ era. 
Current EuroSIDA work aims to explore the underly-
ing reasons for the observed variation, with the goal 
to identify a best practice and to benchmark HIV care.
10 www.eurosurveillance.org
Acknowledgements
The EuroSIDA study group:
The multi-centre study group, EuroSIDA (national coordina-
tors in parenthesis).
Argentina: (M Losso), M Kundro, Hospital JM Ramos Mejia, 
Buenos Aires.
Austria: (B Schmied), Pulmologisches Zentrum der Stadt 
Wien, Vienna; R Zangerle, Medical University Innsbruck, 
Innsbruck.
Belarus: (I Karpov), A Vassilenko, Belarus State Medical 
University, Minsk, VM Mitsura, Gomel State Medical 
University, Gomel; D Paduto, Regional AIDS Centre, 
Svetlogorsk.
Belgium: (N Clumeck), S De Wit, M Delforge, Saint-Pierre 
Hospital, Brussels; E Florence, Institute of Tropical Medicine, 
Antwerp; L Vandekerckhove, University Ziekenhuis Gent, 
Gent.
Bosnia-Herzegovina: (V Hadziosmanovic), Klinicki Centar 
Univerziteta Sarajevo, Sarajevo.
Croatia: (J Begovac), University Hospital of Infectious 
Diseases, Zagreb.
Czech Republic: (L Machala), D Jilich, Faculty Hospital 
Bulovka, Prague; D Sedlacek, Charles University Hospital, 
Plzen.
Denmark: G Kronborg,T Benfield, Hvidovre Hospital, 
Copenhagen; J Gerstoft, T Katzenstein, Rigshospitalet, 
Copenhagen; NF Møller, C Pedersen, Odense University 
Hospital, Odense; L Ostergaard, Skejby Hospital, Aarhus, 
L Wiese, Roskilde Hospital, Roskilde; L N Nielsen, Hillerod 
Hospital, Hillerod.
Estonia: (K Zilmer), West-Tallinn Central Hospital, Tallinn; 
Jelena Smidt, Nakkusosakond Siseklinik, Kohtla-Järve.
Finland: (M Ristola), I Aho, Helsinki University Central 
Hospital, Helsinki.
France: (J-P Viard), Hôtel-Dieu, Paris; P-M Girard, Hospital 
Saint-Antoine, Paris; C Pradier, E Fontas, Hôpital de l'Archet, 
Nice; C Duvivier, Hôpital Necker-Enfants Malades, Paris.
Germany: (J Rockstroh), Universitäts Klinik Bonn; G Behrens, 
Medizinische Hochschule Hannover; O Degen, University 
Medical Center Hamburg-Eppendorf, Infectious Diseases 
Unit, Hamburg; HJ Stellbrink, IPM Study Center, Hamburg; C 
Stefan, JW Goethe University Hospital, Frankfurt; J Bogner, 
Medizinische Poliklinik, Munich; G. Fätkenheuer, Universität 
Köln, Cologne.
Georgia: (N Chkhartishvili) Infectious Diseases, AIDS & 
Clinical Immunology Research Center, Tbilisi
Greece: (P Gargalianos), G Xylomenos, K Armenis, Athens 
General Hospital “G Gennimatas”; H Sambatakou, 
Ippokration General Hospital, Athens.
Hungary: (J Szlávik), Szent Lásló Hospital, Budapest.
Iceland: (M Gottfredsson), Landspitali University Hospital, 
Reykjavik.
Ireland: (F Mulcahy), St. James's Hospital, Dublin.
Israel: (I Yust), D Turner, M Burke, Ichilov Hospital, Tel Aviv; E 
Shahar, G Hassoun, Rambam Medical Center, Haifa; H Elinav, 
M Haouzi, Hadassah University Hospital, Jerusalem; D Elbirt, 
ZM Sthoeger, AIDS Center (Neve Or), Jerusalem.
Italy: (A D’Arminio Monforte), Istituto Di Clinica Malattie 
Infettive e Tropicale, Milan; R Esposito, I Mazeu, C Mussini, 
Università Modena, Modena; F Mazzotta, A Gabbuti, 
Ospedale S Maria Annunziata, Firenze; V Vullo, M Lichtner, 
University di Roma la Sapienza, Rome; M Zaccarelli, A 
Antinori, R Acinapura, M Plazzi, Istituto Nazionale Malattie 
Infettive Lazzaro Spallanzani, Rome; A Lazzarin, A Castagna, 
N Gianotti, Ospedale San Raffaele, Milan; M Galli, A Ridolfo, 
Osp. L. Sacco, Milan.
Latvia: (B Rozentale), Infectology Centre of Latvia, Riga.
Lithuania: (V Uzdaviniene) Vilnius University Hospital 
Santaros Klinikos, Vilnius; R Matulionyte, Centro poliklini-
ka, Vilnius, Vilnius University Hospital Santaros Klinikos, 
Vilnius.
Luxembourg: (T Staub), R Hemmer, Centre Hospitalier, 
Luxembourg.
Netherlands: (P Reiss), Academisch Medisch Centrum bij de 
Universiteit van Amsterdam, Amsterdam.
Norway: (DH Reikvam), A Maeland, J Bruun, Ullevål Hospital, 
Oslo.
Poland: (B Knysz), J Gasiorowski, M Inglot, Medical 
University, Wroclaw; A Horban, E Bakowska, Centrum 
Diagnostyki i Terapii AIDS, Warsaw; R Flisiak, A Grzeszczuk, 
Medical University, Bialystok; M Parczewski, K Maciejewska, 
B Aksak-Was, Medical Univesity, Szczecin; M Beniowski, E 
Mularska, Osrodek Diagnostyki i Terapii AIDS, Chorzow; 
T Smiatacz, M Gensing, Medical University, Gdansk; E 
Jablonowska, E Malolepsza, K Wojcik, Wojewodzki Szpital 
Specjalistyczny, Lodz; I Mozer-Lisewska, Poznan University 
of Medical Sciences, Poznan.
Portugal: (L Caldeira), Hospital Santa Maria, Lisbon; K 
Mansinho, Hospital de Egas Moniz, Lisbon; F Maltez, Hospital 
Curry Cabral, Lisbon.
Romania: (R Radoi), C Oprea, Spitalul Clinic de Boli 
Infectioase si Tropicale: Dr. Victor Babes, Bucuresti.
Russia: (A Panteleev), O Panteleev, St Petersburg AIDS 
Centre, St Peterburg; A Yakovlev, Medical Academy Botkin 
Hospital, St Petersburg; T Trofimora, Novgorod Centre for 
AIDS, Novgorod, I Khromova, Centre for HIV/AIDS & and 
Infectious Diseases, Kaliningrad; E Kuzovatova, Nizhny 
Novgorod Scientific and Research Institute of Epidemiology 
and Microbiology named after Academician I.N. Blokhina, 
Nizhny Novogrod; E Borodulina, E Vdoushkina, Samara State 
Medical University, Samara.
Serbia: (D Jevtovic), The Institute for Infectious and Tropical 
Diseases, Belgrade.
Slovenia: (J Tomazic), University Clinical Centre Ljubljana, 
Ljubljana.
Spain: (JM Gatell), JM Miró, Hospital Clinic Universitari de 
Barcelona, Barcelona; S Moreno, J. M. Rodriguez, Hospital 
Ramon y Cajal, Madrid; B Clotet, A Jou, R Paredes, C Tural, 
J Puig, I Bravo, Hospital Germans Trias i Pujol, Badalona; P 
Domingo, M Gutierrez, G Mateo, MA Sambeat, Hospital Sant 
Pau, Barcelona; JM Laporte, Hospital Universitario de Alava, 
Vitoria-Gasteiz.
11www.eurosurveillance.org
Sweden: (K Falconer), A Thalme, A Sonnerborg, Karolinska 
University Hospital, Stockholm; A Blaxhult, Venhälsan-
Sodersjukhuset, Stockholm; L Flamholc, Malmö University 
Hospital, Malmö.
Switzerland: (A Scherrer), R Weber, University Hospital 
Zurich; M Cavassini, University Hospital Lausanne; A Calmy, 
University Hospital Geneva; H Furrer, University Hospital 
Bern; M Battegay, University Hospital Basel; P Schmid, 
Cantonal Hospital St. Gallen.
Ukraine: A Kuznetsova, Kharkov State Medical University, 
Kharkov; G Kyselyova, Crimean Republican AIDS cen-
tre, Simferopol; M Sluzhynska, Lviv Regional HIV/AIDS 
Prevention and Control CTR, Lviv.
United Kingdom: (B Gazzard), St. Stephen's Clinic, Chelsea 
and Westminster Hospital, London; AM Johnson, E Simons, 
S Edwards, Mortimer Market Centre, London; A Phillips, 
MA Johnson, A Mocroft, Royal Free and University College 
Medical School, London (Royal Free Campus); C Orkin, Royal 
London Hospital, London; J Weber, G Scullard, Imperial 
College School of Medicine at St. Mary's, London; A Clarke, 
Royal Sussex County Hospital, Brighton; C Leen, Western 
General Hospital, Edinburgh.
The following centres have previously contributed data to 
EuroSIDA:
Infectious Diseases Hospital, Sofia, Bulgaria
Hôpital de la Croix Rousse, Lyon, France
Hôpital de la Pitié-Salpétière, Paris, France
Unité INSERM, Bordeaux, France
Hôpital Edouard Herriot, Lyon, France
Bernhard Nocht Institut für Tropenmedizin, Hamburg, 
Germany
1st I.K.A Hospital of Athens, Athens, Greece
Ospedale Riuniti, Divisione Malattie Infettive, Bergamo, Italy
Ospedale di Bolzano, Divisione Malattie Infettive, Bolzano, 
Italy
Ospedale Cotugno, III Divisione Malattie Infettive, Napoli, 
Italy
Dérer Hospital, Bratislava, Slovakia
Hospital Carlos III, Departamento de Enfermedades 
Infecciosas, Madrid, Spain
Kiev Centre for AIDS, Kiev, Ukraine
Luhansk State Medical University, Luhansk, Ukraine
Odessa Region AIDS Center, Odessa, Ukraine
EuroSIDA steering committee:
J Gatell, B Gazzard, A Horban, I Karpov, M Losso, A d’Arminio 
Monforte, C Pedersen, M Ristola, A Phillips, P Reiss, J 
Lundgren, J Rockstroh, A Scherrer, I Aho, LD Rasmussen, 
V Svedhem, G Wandeler, C Pradier, N Chkhartishvili, R 
Matulionyte, C Oprea, JD Kowalska, J Begovac, J Miro, 
G Guaraldi, R Paredes. Chair: J Rockstroh. Vice chair: R 
Paredes. Study Co-leads: A Mocroft, O Kirk
EuroSIDA staff: Coordinating Centre Staff: O Kirk, L Peters, 
A Bojesen, D Raben, D Kristensen, K Laut, JF Larsen, D 
Podlekareva. Statistical Staff: A Mocroft, A Phillips, A Cozzi-
Lepri, L Shepherd, S Amele, A Pelchen-Matthews.
Funding:
EuroSIDA was supported by the European Union’s Seventh 
Framework Programme for research, technological develop-
ment and demonstration under EuroCoord grant agreement 
no. 260694. Current support includes unrestricted grants by 
ViiV Healthcare LLC, GlaxoSmithKline R&D Limited, Janssen 
Scientific Affairs, Janssen R&D, Bristol-Myers Squibb 
Company, Merck Sharp & Dohme Corp, Gilead Sciences. The 
participation of centres from Switzerland was supported by 
The Swiss National Science Foundation (grant 148522). The 
study is also supported by a grant (grant number DNRF126) 
from the Danish National Research Foundation.
Conflict of interest
None declared.
Authors’ contributions
Kamilla Laut, Ole Kirk, Amanda Mocroft and Jens Lundgren 
conceived the idea of the study. Leah Shepherd carried 
out the statistical analysis. Kamilla Laut, Ole Kirk, Amanda 
Mocroft, Jens Lundgren and Leah Shepherd contributed to 
the data analysis and interpretation of the results. Roxana 
Radoi, Igor Karpov, Milosz Parczewski, Cristina Mussini, 
Fernando Maltez, Marcelo Losso, Nikoloz Chkhartishvili, 
Hila Elinav, Helen Kovari, Anders Blaxhult, Robert Zangerle, 
Tatiana Trofimova, Malgorzata Inglot, Kai Zilmer, Elena 
Kuzovatova, Thérèse Staub and Dorthe Raben contributed 
with data collection. Kamilla Laut wrote the article with input 
and review from all authors. All authors have read and ap-
proved the final article.
References
1. Mackenbach JP, Karanikolos M, McKee M. The unequal health 
of Europeans: successes and failures of policies. Lancet. 
2013;381(9872):1125-34.  https://doi.org/10.1016/S0140-
6736(12)62082-0  PMID: 23541053 
2. European Centre for Disease Prevention and Control 
(ECDC). Thematic report: Continuum of HIV care. 
Monitoring implementation of the Dublin Declaration on 
Partnership to Fight HIV/AIDS in Europe and Central Asia: 
2017 progress report. Stockholm: ECDC; 2017. Available 
from https://ecdc.europa.eu/en/publications-data/
thematic-report-continuum-hiv-care
3. European Centre for Disease Prevention and Control (ECDC)/
World Health Organization Regional Office for Europe (WHO/
Europe). HIV/AIDS surveillance in Europe 2013. Stockholm: 
ECDC; 2014. Available from: https://ecdc.europa.eu/en/
publications-data/hivaids-surveillance-europe-2013
4. Organisation for Economic Cooperation and Development 
(OECD)/European Union. Health at a Glance: Europe 2014. 
Paris: OECD Publishing; 2014. Available from: http://dx.doi.
org/ https://doi.org/10.1787/health_glance_eur-2014-en 
5. Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The 
spectrum of engagement in HIV care and its relevance to test-
and-treat strategies for prevention of HIV infection. Clin Infect 
Dis. 2011;52(6):793-800.  https://doi.org/10.1093/cid/ciq243  
PMID: 21367734 
6. Medland NA, McMahon JH, Chow EPF, Elliott JH, Hoy JF, 
Fairley CK. The HIV care cascade: a systematic review of data 
sources, methodology and comparability. J Int AIDS Soc. 
2015;18(1):20634.  https://doi.org/10.7448/IAS.18.1.20634  
PMID: 26626715 
12 www.eurosurveillance.org
7. Kohler P, Schmidt AJ, Cavassini M, Furrer H, Calmy A, 
Battegay M, et al. The HIV care cascade in Switzerland: 
reaching the UNAIDS/WHO targets for patients diagnosed 
with HIV. AIDS. 2015;29(18):2509-15.  https://doi.org/10.1097/
QAD.0000000000000878  PMID: 26372488 
8. Pokrovskaya A, Popova A, Ladnaya N, Yurin O. The cascade 
of HIV care in Russia, 2011-2013. J Int AIDS Soc. 2014;17(4) 
Suppl 3;19506.  https://doi.org/10.7448/IAS.17.4.19506  PMID: 
25394015 
9. Helleberg M, Häggblom A, Sönnerborg A, Obel N. HIV care in 
the Swedish-Danish HIV cohort 1995-2010, closing the gaps. 
PLoS One. 2013;8(8):e72257.  https://doi.org/10.1371/journal.
pone.0072257  PMID: 23967292 
10. Diaz A, Sobrino P, Amo J, Moreno S, Diez M, Hospitalaria E. La 
Cascada del Tratamiento en España: Primeras Estimaciones. 
[The treatment cascade in Spain: First estimates]. VI Congreso 
Nacional GeSIDA; 25-28 Nov 2014, Malaga, Spain. P081. 
Spanish. Available from: http://www.opttest.eu/Portals/0/
Publications/Annex%2030_20131102_WP4%20POS_ES_PS.pdf
11. Chkhartishvili N, Sharavdze L, Chokoshvili O, DeHovitz JA, 
del Rio C, Tsertsvadze T. The cascade of care in the Eastern 
European country of Georgia. HIV Med. 2015;16(1):62-6.  
https://doi.org/10.1111/hiv.12172  PMID: 24919923 
12. Van Beckhoven D, Florence E, Ruelle J, Deblonde J, Verhofstede 
C, Callens S, et al. Good continuum of HIV care in Belgium 
despite weaknesses in retention and linkage to care among 
migrants. BMC Infect Dis. 2015;15(1):496.  https://doi.
org/10.1186/s12879-015-1230-3  PMID: 26530500 
13. Yin Z, Brown AE, Hughes G, Nardone A, Gill ON, Delpech VC, et 
al. HIV in the United Kingdom 2014 Report: data to end 2013. 
London: Public Health England; 2014. Available from: https://
assets.publishing.service.gov.uk/government/uploads/
system/uploads/attachment_data/file/401662/2014_PHE_
HIV_annual_report_draft_Final_07-01-2015.pdf
14. Laisaar K, Raag M, Rasva H, Uusküla A. Engagement in the 
continuum of HIV care in Estonia. 9th International Conference 
on HIV Treatment and Prevention Adherence; 8-10 Jun 2014, 
Miami, United States. Abstract 337. Available from: http://
www.iapac.org/AdherenceConference/Adherence_2014.html
15. Supervie V, Costagliola D. The spectrum of engagement in 
HIV care in France: strengths and gaps. 20th conference on 
Retroviruses and Opportunistic Infections (CROI); 3-6 Mar 
2013, Atlanta, United States. Abstract 1030.
16. Tuite H, Horgan M, Mallon PW, McConkey SJ, Mooka B, 
Mulcahy F, et al. Patients Accessing Ambulatory Care for HIV-
infection: Epidemiology and Prevalence Assessment. Ir Med J. 
2015;108(7):199-202. PMID: 26349347 
17. Van Sighem AA, Gras L, Smit C, Stolte I, Reiss P, Arends CJ, 
et al. Monitoring report 2014, human immunodeficiency virus 
(HIV) infection in the Netherlands. Amsterdam: Stichting HIV 
Monitoring; 2014. Available from: https://www.hiv-monitoring.
nl/files/8914/1527/1076/SHM_Monitoring_report_2014.pdf
18. The Joint United Nations Programme on HIV/AIDS (UNAIDS). 
90-90-90. An ambitious treatment target to help end the AIDS 
epidemic. Geneva: UNAIDS; 2014. Available from: http://www.
unaids.org/en/resources/documents/2017/90-90-90
19. Levi J, Raymond A, Pozniak A, Vernazza P, Kohler P, Hill A. 
Can the UNAIDS 90-90-90 target be achieved? A systematic 
analysis of national HIV treatment cascades. BMJ Glob 
Health. 2016;1(2):e000010.  https://doi.org/10.1136/
bmjgh-2015-000010  PMID: 28588933 
20. Drew RS, Rice B, Rüütel K, Delpech V, Attawell KA, Hales DK, et 
al. HIV continuum of care in Europe and Central Asia. HIV Med. 
2017;18(7):490-9.  https://doi.org/10.1111/hiv.12480  PMID: 
28117527 
21. Lourenço L, Hull M, Nosyk B, Montaner JSG, Lima VD. The 
need for standardisation of the HIV continuum of care. Lancet 
HIV. 2015;2(6):e225-6.  https://doi.org/10.1016/S2352-
3018(15)00086-7  PMID: 26423191 
22. Haber N, Pillay D, Porter K, Bärnighausen T. Constructing 
the cascade of HIV care: methods for measurement. Curr 
Opin HIV AIDS. 2016;11(1):102-8.  https://doi.org/10.1097/
COH.0000000000000212  PMID: 26545266 
23. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, 
d’Arminio Monforte A, et al. Decline in the AIDS and death 
rates in the EuroSIDA study: an observational study. Lancet. 
2003;362(9377):22-9.  https://doi.org/10.1016/S0140-
6736(03)13802-0  PMID: 12853195 
24. Mocroft A, Kirk O, Aldins P, Chies A, Blaxhult A, Chentsova 
N, et al. EuroSIDA study group. Loss to follow-up in 
an international, multicentre observational study. HIV 
Med. 2008;9(5):261-9.  https://doi.org/10.1111/j.1468-
1293.2008.00557.x  PMID: 18400074 
25. Lundgren JD, Babiker AG, Gordin F, Emery S, Grund 
B, Sharma S, et al. Initiation of antiretroviral therapy 
in early asymptomatic HIV infection. N Engl J Med. 
2015;373(9):795-807.  https://doi.org/10.1056/NEJMoa1506816  
PMID: 26192873 
26. Battegay M, Lundgren JD, Ryom L. Guidelines version 
8.2. Brussels: European AIDS Clinical Society (EACS); 
2017. Available from: http://www.eacsociety.org/files/
guidelines_8.2-english.pdf
27. World Health Organization (WHO). Guideline on when to start 
antiretroviral therapy and on pre-exposure prophylaxis for HIV. 
Geneva: WHO; 2015. Available from: http://www.who.int/hiv/
pub/guidelines/earlyrelease-arv/en/
28. Supervie V, Marty L, Lacombe J-M, Dray-Spira R, Costagliola 
DFHDH-ANRS CO4 study group. Looking beyond the cascade 
of HIV care to end the AIDS epidemic: Estimation of the 
time interval from HIV infection to viral suppression. J 
Acquir Immune Defic Syndr. 2016;73(3):348-55.  https://doi.
org/10.1097/QAI.0000000000001120  PMID: 27351889 
29. Hall HI, Frazier EL, Rhodes P, Holtgrave DR, Furlow-Parmley 
C, Tang T, et al. Differences in human immunodeficiency 
virus care and treatment among subpopulations in the United 
States. JAMA Intern Med. 2013;173(14):1337-44.  https://doi.
org/10.1001/jamainternmed.2013.6841  PMID: 23780395 
30. Kossarova L, Blunt I, Bardsley M. Focus on: International 
comparisons of healthcare quality. London: The Health 
Foundation and the Nuffield Trust; 2015. Available 
from: https://www.nuffieldtrust.org.uk/research/
focus-on-international-comparisons-of-healthcare-quality
31. Laut KG, Shepherd LC, Pedersen C, Rockstroh JK, Sambatakou 
H, Paduta D, et al. Associations between HIV-RNA-
based indicators and virological and clinical outcomes. 
AIDS. 2016;30(12):1961-72.  https://doi.org/10.1097/
QAD.0000000000001144  PMID: 27149091 
32. Sungkanuparph S, Overton ET, Seyfried W, Groger RK, 
Fraser VJ, Powderly WG. Intermittent episodes of detectable 
HIV viremia in patients receiving nonnucleoside reverse-
transcriptase inhibitor-based or protease inhibitor-based 
highly active antiretroviral therapy regimens are equivalent in 
incidence and prognosis. Clin Infect Dis. 2005;41(9):1326-32.  
https://doi.org/10.1086/496985  PMID: 16206110 
33. Nosyk B, Montaner JSG, Colley G, Lima VD, Chan K, Heath K, et 
al. The cascade of HIV care in British Columbia, Canada, 1996-
2011: a population-based retrospective cohort study. Lancet 
Infect Dis. 2014;14(1):40-9.  https://doi.org/10.1016/S1473-
3099(13)70254-8  PMID: 24076277 
34. Cahn P, Andrade-Villanueva J, Arribas JR, Gatell JM, Lama 
JR, Norton M, et al. Dual therapy with lopinavir and ritonavir 
plus lamivudine versus triple therapy with lopinavir and 
ritonavir plus two nucleoside reverse transcriptase inhibitors 
in antiretroviral-therapy-naive adults with HIV-1 infection: 48 
week results of the randomised, open label, non-inferiority 
GARDEL trial. Lancet Infect Dis. 2014;14(7):572-80.  https://doi.
org/10.1016/S1473-3099(14)70736-4  PMID: 24783988 
35. Arribas JR, Girard PM, Landman R, Pich J, Mallolas J, Martínez-
Rebollar M, et al. Dual treatment with lopinavir-ritonavir plus 
lamivudine versus triple treatment with lopinavir-ritonavir 
plus lamivudine or emtricitabine and a second nucleos(t)ide 
reverse transcriptase inhibitor for maintenance of HIV-1 viral 
suppression (OLE): a randomised, open-label, non-inferiority 
trial. Lancet Infect Dis. 2015;15(7):785-92.  https://doi.
org/10.1016/S1473-3099(15)00096-1  PMID: 26062880 
36. Laut K, Shepherd L, Gottfredsson M, Sedlacek D, Knysz B, 
Begovac J, et al. Variation in ART-coverage and virological 
suppression among HIV key populations. HepHIV 2017 
Conference; 31 Jan-2 Feb 2017, Malta. P01/14.
License and copyright
This is an open-access article distributed under the terms of 
the Creative Commons Attribution (CC BY 4.0) Licence. You 
may share and adapt the material, but must give appropriate 
credit to the source, provide a link to the licence, and indi-
cate if changes were made.
This article is copyright of the authors, 2018.
